AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1693037 — intervention group
Group type: COMPARATOR
Intervention: Chlormadinone acetate (CMA) 50 mg/day for 12 weeks
Number of subjects: 58
Study 331522 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil intraluminal chemotherapy
Number of subjects: 500
Study 30949704 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lefamulin (150 mg, q12h)
Number of subjects: 0
Study 30949704 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lefamulin (600 mg IR tablet)
Number of subjects: 0
Study 30949704 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lefamulin (3 × 200 mg capsule)
Number of subjects: 0
Study 30949704 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lefamulin (IR) in fasted state
Number of subjects: 0
Study 30949704 — intervention group
Group type: COMPARATOR
Intervention: Repeated doses of lefamulin (IR, q12h)
Number of subjects: 0
Study 30949704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27804233 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan treatment
Number of subjects: 82
Study 26209860 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (4 mg/d)
Number of subjects: 19
Study 26209860 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride (200 mg/d)
Number of subjects: 19
Study 26209860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 23566360 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based intervention with four telephone contacts and print materials
Number of subjects: 394
Study 23566360 — intervention group
Group type: COMPARATOR
Intervention: Control condition with generic print materials only
Number of subjects: 394
Study 21611863 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Slow (1 ml/min injection of hyperbaric 0.5% bupivacaine)
Number of subjects: 66
Study 21611863 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Extra Slow (0.5 ml/min injection of hyperbaric 0.5% bupivacaine)
Number of subjects: 66
Study 19912734 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanxue Mingmu Tablet combined with conventional treatment
Number of subjects: 34
Study 19912734 — intervention group
Group type: COMPARATOR
Intervention: Xueshuantong Tablet combined with conventional treatment
Number of subjects: 34
Study 16698412 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal lorazepam (100 microg/kg)
Number of subjects: 160
Study 16698412 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular paraldehyde (0.2 mL/kg)
Number of subjects: 160
Study 15138466 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0
Study 15138466 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy as perceived by medical oncologists
Number of subjects: 0
Study 11336276 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin-layer chromatography (TLC) screening method for drug quality
Number of subjects: 40
Study 11336276 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmatory analysis for RMP
Number of subjects: 40
Study 11336276 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmatory analysis for INH
Number of subjects: 40
Study 9466167 — intervention group
Group type: EXPERIMENTAL
Intervention: RS-8359 100 mg/day
Number of subjects: 2
Study 9466167 — intervention group
Group type: EXPERIMENTAL
Intervention: RS-8359 200 mg/day
Number of subjects: 2
Study 9466167 — intervention group
Group type: COMPARATOR
Intervention: Moclobemide 300 mg/day
Number of subjects: 2
Study 9466167 — intervention group
Group type: EXPERIMENTAL
Intervention: RS-8359 (all doses)
Number of subjects: 2
Study 7949088 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO (150 IU/kg/day)
Number of subjects: 272
Study 7949088 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO
Number of subjects: 272
Study 7949088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study 2833980 — intervention group
Group type: EXPERIMENTAL
Intervention: 21G needle passed into the tumour at least 10 times
Number of subjects: 19
Study 2833980 — intervention group
Group type: COMPARATOR
Intervention: 23G needle
Number of subjects: 19
Study 2833980 — intervention group
Group type: COMPARATOR
Intervention: 21G needle
Number of subjects: 19
Study 2833980 — intervention group
Group type: COMPARATOR
Intervention: 19G needle
Number of subjects: 19
Study 2833980 — intervention group
Group type: COMPARATOR
Intervention: 5 passes
Number of subjects: 19
Study 2833980 — intervention group
Group type: COMPARATOR
Intervention: 10 passes
Number of subjects: 19
Study 2833980 — intervention group
Group type: COMPARATOR
Intervention: 15 passes
Number of subjects: 19
Study 29531468 — intervention group
Group type: EXPERIMENTAL
Intervention: PGA plus stent placement
Number of subjects: 70
Study 29531468 — intervention group
Group type: COMPARATOR
Intervention: Stent placement alone
Number of subjects: 70
Study 28534875 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 IU oxytocin
Number of subjects: 17
Study 28534875 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 IU oxytocin
Number of subjects: 17
Study 28534875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 26231052 — intervention group
Group type: EXPERIMENTAL
Intervention: Incontinence Utility Index (IUI)
Number of subjects: 1105
Study 23926589 — intervention group
Group type: EXPERIMENTAL
Intervention: 11 different toothbrushes (Colgate Massager, Butler 311, Gum Super Tip 463, Oral-B Indicator 35, Colgate Omni, Gum Technique 493)
Number of subjects: 48
Study 23926589 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Massager
Number of subjects: 48
Study 23926589 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-B Indicator 35
Number of subjects: 48
Study 23926589 — intervention group
Group type: COMPARATOR
Intervention: Control (no toothbrushing)
Number of subjects: 48
Study 21148715 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathe-Easy home (BEH)
Number of subjects: 102
Study 21148715 — intervention group
Group type: COMPARATOR
Intervention: Previous asthma-control intervention (control group)
Number of subjects: 102
Study 18978620 — intervention group
Group type: EXPERIMENTAL
Intervention: Squat training with whole-body low-frequency vibration (SQTV)
Number of subjects: 30
Study 18978620 — intervention group
Group type: EXPERIMENTAL
Intervention: Squat training without vibration (SQT)
Number of subjects: 30
Study 18978620 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 30
Study 18978620 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-cm depth jump Pmax percent change
Number of subjects: 30
Study 18978620 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-kg squat jump Pmax
Number of subjects: 30
Study 18978620 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-kg squat jump Pmax/kg percent change
Number of subjects: 30
Study 17120390 — intervention group
Group type: EXPERIMENTAL
Intervention: xenograft plus fibronectin
Number of subjects: 24
Study 17120390 — intervention group
Group type: COMPARATOR
Intervention: xenograft without fibronectin
Number of subjects: 24
Study 15650065 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma arc lamp
Number of subjects: 20
Study 15650065 — intervention group
Group type: COMPARATOR
Intervention: Conventional tungsten quartz halogen lamp
Number of subjects: 20
Study 11317156 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training program (n = 13)
Number of subjects: 26
Study 11317156 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control group (n = 13)
Number of subjects: 26
Study 9146907 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus duration of 200 to 1500 ms
Number of subjects: 0
Study 9146907 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 7711427 — intervention group
Group type: EXPERIMENTAL
Intervention: captopril
Number of subjects: 15
Study 7711427 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study 2895695 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (game of squash)
Number of subjects: 6
Study 2895695 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest after exercise
Number of subjects: 6
Study 2895695 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta 2-antagonist pretreatment
Number of subjects: 6
Study 31221941 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocytapheresis (LCAP) therapy (n = 20)
Number of subjects: 51
Study 31221941 — intervention group
Group type: COMPARATOR
Intervention: Disease-modifying antirheumatic drugs (DMARDs) (n = 31)
Number of subjects: 51
Study 30621787 — intervention group
Group type: EXPERIMENTAL
Intervention: Back2School (modular transdiagnostic cognitive behavioral therapy)
Number of subjects: 160
Study 30621787 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 160
Study 30621787 — intervention group
Group type: EXPERIMENTAL
Intervention: Back2School
Number of subjects: 160
Study 28687477 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 827
Study 28687477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 827
Study 26355172 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-drill group
Number of subjects: 40
Study 26355172 — intervention group
Group type: COMPARATOR
Intervention: multiple-drill group
Number of subjects: 40
Study 23398859 — intervention group
Group type: EXPERIMENTAL
Intervention: Tampon use (two types of tampons)
Number of subjects: 7
Study 23398859 — intervention group
Group type: COMPARATOR
Intervention: Pad use
Number of subjects: 7
Study 21178123 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol mixed with cranberry juice (97 ± 3 ml glycerol + equal portion of cranberry juice; n = 9)
Number of subjects: 16
Study 21178123 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (water + cranberry juice; n = 7)
Number of subjects: 16
Study 18778333 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxaverine (150 mg, administered i.v.)
Number of subjects: 16
Study 18778333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 17359649 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 41
Study 17359649 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 41
Study 15240597 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutropin Depot 0.75 mg/kg once per month
Number of subjects: 138
Study 15240597 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutropin Depot 0.75 mg/kg twice per month
Number of subjects: 138
Study 15240597 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutropin Depot 1.5 mg/kg once per month
Number of subjects: 138
Study 15240597 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutropin Depot (all dosing regimens)
Number of subjects: 138
Study 12234957 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase-velocity MRI (PV-MRI)
Number of subjects: 15
Study 12234957 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung perfusion scintigraphy
Number of subjects: 15
Study 9722130 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/day for 10 consecutive days starting on the 13th day of the menstrual cycle
Number of subjects: 24
Study 9722130 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 24
Study 8002320 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg, increased to 40 mg based on response)
Number of subjects: 122
Study 8002320 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical to fluoxetine)
Number of subjects: 122
Study 8002320 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 122
Study 8002320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 3404502 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo ultrasound
Number of subjects: 79
Study 3404502 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentist-administered ultrasound
Number of subjects: 79
Study 3404502 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-applied facial massage
Number of subjects: 79
Study 3404502 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 79
Study 31544925 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led care
Number of subjects: 1375
Study 31544925 — intervention group
Group type: COMPARATOR
Intervention: Usual-care
Number of subjects: 1375
Study 31544925 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led care (experienced centres)
Number of subjects: 1375
Study 31544925 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led care (less experienced centres)
Number of subjects: 1375
Study 29735469 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 0
Study 29735469 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 0
Study 29735469 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 0
Study 29735469 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 0
Study 27560168 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone (30 mg for 4 weeks, then 45 mg for 8 weeks)
Number of subjects: 68
Study 27560168 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone
Number of subjects: 68
Study 27560168 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 68
Study 25720332 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraaortic balloon pump (IABP) support
Number of subjects: 41
Study 25720332 — intervention group
Group type: COMPARATOR
Intervention: No IABP support (Control)
Number of subjects: 41
Study 25720332 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvascular perfusion
Number of subjects: 41
Study 25720332 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcirculatory parameters
Number of subjects: 41
Study 23561603 — intervention group
Group type: EXPERIMENTAL
Intervention: Trypan blue (TB)
Number of subjects: 25
Study 23561603 — intervention group
Group type: COMPARATOR
Intervention: Indocyanine green (ICG)
Number of subjects: 25
Study 20598974 — intervention group
Group type: EXPERIMENTAL
Intervention: Elinogrel (intravenous and oral formulations)
Number of subjects: 0
Study 20598974 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study 19133491 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (Remeron)
Number of subjects: 0
Study 19133491 — intervention group
Group type: COMPARATOR
Intervention: Serotonin reuptake inhibitors
Number of subjects: 0
Study 19133491 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine (Effexor)
Number of subjects: 0
Study 16374157 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonbronchoscopic lavage
Number of subjects: 41
Study 16374157 — intervention group
Group type: COMPARATOR
Intervention: Bronchoscopic lavage
Number of subjects: 41
Study 12824830 — intervention group
Group type: EXPERIMENTAL
Intervention: Green argon laser photocoagulation for soft drusen
Number of subjects: 52
Study 12824830 — intervention group
Group type: EXPERIMENTAL
Intervention: Before macular atrophy development
Number of subjects: 52
Study 12824830 — intervention group
Group type: EXPERIMENTAL
Intervention: After the appearance of macular atrophy
Number of subjects: 52
Study 11136293 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg microencapsulated octreotide acetate intramuscularly
Number of subjects: 0
Study 8799516 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous phylloquinone (vitamin K1) mixed micelles formulation (Konakion MM)
Number of subjects: 30
Study 8799516 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular phylloquinone (vitamin K1) mixed micelles formulation (Konakion MM)
Number of subjects: 30
Study 1629383 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (average maximum dosage 2.2 mg)
Number of subjects: 35
Study 1629383 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (average maximum dosage 97.5 mg)
Number of subjects: 35
Study 1629383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 6483520 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release theophylline sprinkle preparation (fasting)
Number of subjects: 12
Study 6483520 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release theophylline sprinkle preparation (after standardized meal)
Number of subjects: 12
Study 6483520 — intervention group
Group type: COMPARATOR
Intervention: Intravenous theophylline
Number of subjects: 12
Study 29537451 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarecycline 1.5 mg/kg
Number of subjects: 285
Study 29537451 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarecycline 3.0 mg/kg
Number of subjects: 285
Study 29537451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study 28139568 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chemoradiotherapy (CRT) with 75 mg/m2 temozolomide (TMZ) followed by 200 mg/m2 TMZ for 5 days every 28 days
Number of subjects: 107
Study 28139568 — intervention group
Group type: COMPARATOR
Intervention: Alternative treatments
Number of subjects: 107
Study 24907874 — intervention group
Group type: EXPERIMENTAL
Intervention: O293 (oxygen from concentrators)
Number of subjects: 60
Study 24907874 — intervention group
Group type: COMPARATOR
Intervention: O293N2O (oxygen from concentrators and nitrous oxide)
Number of subjects: 60
Study 22414228 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide treatment for 8 weeks
Number of subjects: 367
Study 20039413 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (1,000 mg) administered on days 1, 15, 168, and 182
Number of subjects: 257
Study 20039413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study 20039413 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 257
Study 18385912 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil (10 mg)
Number of subjects: 0
Study 18385912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16037151 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (S)
Number of subjects: 31
Study 16037151 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (D)
Number of subjects: 31
Study 14577063 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 131
Study 14577063 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized trials
Number of subjects: 131
Study 14577063 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonrandomized studies
Number of subjects: 131
Study 10894282 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir 400 mg twice daily plus Indinavir 400 mg twice daily with either Zidovudine/Lamivudine (49%), Stavudine/Lamivudine (38%), or Stavudine/Didanosine (13%)
Number of subjects: 90
Study 10894282 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir 400 mg twice daily plus Indinavir 400 mg twice daily
Number of subjects: 90
Study 10894282 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir/Indinavir plus double nucleoside therapy
Number of subjects: 90
Study 8669994 — intervention group
Group type: EXPERIMENTAL
Intervention: Back school program (3 sessions of 90 minutes each at 0, 1, and 8 weeks)
Number of subjects: 168
Study 8669994 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment program (daily physiotherapy)
Number of subjects: 168
Study 8669994 — intervention group
Group type: EXPERIMENTAL
Intervention: Back school program
Number of subjects: 168
Study 8669994 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment program
Number of subjects: 168
Study 1508127 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 300 mg/day, orally, starting the day before surgery and continuing for 7 consecutive days
Number of subjects: 50
Study 1508127 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned in the abstract)
Number of subjects: 50
Study 6308755 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivmecillinam-pivampicillin (PMPA) 200 + 250 mg b.i.d.
Number of subjects: 67
Study 6308755 — intervention group
Group type: COMPARATOR
Intervention: Pivmecillinam (PM) 400 mg b.i.d.
Number of subjects: 67
Study 31974708 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy (POCT)
Number of subjects: 582
Study 31974708 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (Control)
Number of subjects: 582
Study 29241383 — intervention group
Group type: COMPARATOR
Intervention: 600 µg buccal misoprostol
Number of subjects: 0
Study 29241383 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg oral TA plus 600 µg buccal misoprostol
Number of subjects: 0
Study 29241383 — intervention group
Group type: COMPARATOR
Intervention: 10 IU oxytocin IV
Number of subjects: 0
Study 29710132 — intervention group
Group type: EXPERIMENTAL
Intervention: Music festival visit for 4.5 hours
Number of subjects: 51
Study 29710132 — intervention group
Group type: COMPARATOR
Intervention: Earplug use
Number of subjects: 51
Study 29710132 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantity of alcohol use
Number of subjects: 51
Study 29710132 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug use
Number of subjects: 51
Study 29710132 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 51
Study 29710132 — intervention group
Group type: COMPARATOR
Intervention: Earplug group
Number of subjects: 51
Study 26829348 — intervention group
Group type: EXPERIMENTAL
Intervention: Valve Catheter (VC)
Number of subjects: 49
Study 24619189 — intervention group
Group type: EXPERIMENTAL
Intervention: PTNS (n = 16)
Number of subjects: 33
Study 24619189 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 17)
Number of subjects: 33
Study 21927922 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg every 6 months)
Number of subjects: 250
Study 21927922 — intervention group
Group type: COMPARATOR
Intervention: Alendronate (70 mg once weekly)
Number of subjects: 250
Study 21927922 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab after alendronate
Number of subjects: 250
Study 21927922 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate after denosumab
Number of subjects: 250
Study 21927922 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 250
Study 21029199 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-game performance
Number of subjects: 20
Study 21029199 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue index
Number of subjects: 20